Elevance Health, a prominent health insurer operating Blue Cross and Blue Shield health plans in 14 states, recently reported nearly $6 billion in profits for the year 2024. This impressive figure includes $413 million in profits in the fourth quarter alone, despite facing challenges with rising medical expenses from patients enrolled in its Medicaid plans.
The health insurer, like many others in the industry, has been grappling with escalating costs due to an influx of patients seeking medical treatment. This surge in patient claims is attributed to a pent-up demand for healthcare services that were postponed during the Covid-19 pandemic. Elevance Health, in particular, has been experiencing a significant increase in sick patients covered by its Medicaid plans.
As a result, Elevance’s benefit expense ratio, which represents the percentage of premium revenue allocated towards medical costs, saw a substantial rise. In the fourth quarter, the benefit expense ratio reached 92.4%, marking a 320 basis points increase compared to the previous year. For the full year, the ratio stood at 88.5%, reflecting a 150 basis points year-over-year increase.
Despite the challenges faced, Elevance Health managed to maintain a strong financial performance. The fourth quarter net income, however, was halved to $418 million, or $1.81 per share, compared to $856 million, or $3.63 per share in the same period last year. For the entire year of 2024, net income remained relatively flat at $5.98 billion, or $25.68 per share, compared to $5.987 billion, or $25.22 per share in 2023. Total revenue also saw a 6.6% increase to $45.4 billion in the fourth quarter and a 3.3% increase to $177 billion for the entire year.
Despite the financial success, Elevance Health experienced a decline in health plan members by the end of the year, primarily due to a drop in Medicaid customers. The conclusion of the U.S. Public Health Emergency in May 2023 following the Covid-19 pandemic had a significant impact on health insurers administering Medicaid coverage, as states conducted Medicaid redeterminations to verify eligibility.
Elevance Health’s CEO, Gail Boudreaux, emphasized the company’s commitment to providing value to its members and care providers by offering simple, affordable, and accessible healthcare. The company’s Carelon business, which includes medical care providers and the pharmacy benefit management service CarelonRx, reported a notable 19% increase in operating revenue to $14.7 billion in the fourth quarter of 2024.
Looking ahead to 2025, Elevance Health remains focused on simplifying the healthcare experience, enhancing the impact of Carelon, and implementing innovative care models to achieve sustainable growth in the long run. The company’s dedication to improving operations and responding to industry challenges positions them for continued success in the dynamic healthcare landscape.
